1785764-26-2

Basic information

• Product Name: 5,6-Diamino-1,3-diethyluracil Hydrochloride
• Synonyms: 5,6-Diamino-1,3-diethyluracil Hydrochloride;5,6-Diamino-1,3-diethyl-2,4(1H,3H)-pyrimidinedione hydrochloride;5,6-diamino-1,3-diethylpyrimidine-2,4(1H,3H)-dione hydrochloride
• CAS NO: 1785764-26-2
• Molecular Formula: C8H15ClN4O2
• Molecular Weight: 234.69
• EINECS: -0
• Mol File: 1785764-26-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 235.0 to 239.0 °C
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5,6-Diamino-1,3-diethyluracil Hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Diamino-1,3-diethyluracil Hydrochloride(1785764-26-2)
• EPA Substance Registry System: 5,6-Diamino-1,3-diethyluracil Hydrochloride(1785764-26-2)

Safety Data

• Hazardous Substances Data: 1785764-26-2(Hazardous Substances Data)

Usage

General Description

5,6-Diamino-1,3-diethyluracil Hydrochloride, also known as ethylhydantoin hydrochloride, is a chemical compound used in the pharmaceutical industry as an anticonvulsant and sedative. It is a derivative of hydantoin and is commonly used in the treatment of epilepsy and other seizure disorders. The compound works by modulating voltage-gated sodium channels, which helps to control and prevent abnormal electrical activity in the brain. It is often administered orally in the form of tablets or capsules and is typically prescribed by a healthcare professional. 5,6-Diamino-1,3-diethyluracil Hydrochloride is considered to be an important medication in the management of epilepsy and has been found to be effective in reducing the frequency and severity of seizures in patients.

Upstream product

• 89073-60-9 6-amino-1,3-diethyl-5-nitroso-1H,3H-pyrimidine-2,4-dione 
• 22390-04-1 1,3-diethyluracil 

Downstream Products

• 155271-84-4 (E)-8-(3-bromostyryl)-1,3-diethyl-1H-purine-2,6(3H,7H)-dione 

Relevant articles and documents

Novel preparation method for Istradefylline

The invention relates to a preparation method for Istradefylline represented by a formula (I) shown in the description. The method comprises the following steps: subjecting 6-amino-1,3-diethyl-5-nitroso-1H-pyrimid-2,4-dione represented by a formula (II) shown in the description, which serves as a raw material, to catalytic reduction and salt forming, so as to obtain 5,6-diamino-1,3-diethyl-1H-pyrimid-2,4-dione hydrochloride represented by a formula (III) shown in the description; then, carrying out acetylation on the compound (III), so as to obtain N-(6-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimid-5-yl)acetamide represented by a formula (IV) shown in the description; carrying out further ring closing, so as to obtain 1,3-diethyl-8-methyl-1H-purin-2,6(3H,7H)-dione represented by a formula (V) shown in the description; and carrying out methylation on the compound (V) firstly, and then, subjecting the methylation product to a condensation reaction with veratraldehyde represented by a formula (VII) shown in the description, thereby obtaining the end product Istradefylline. According to the novel preparation method for the Istradefylline, provided by the invention, raw materials, which are readily available industrially and are low in price, are used, the production process is more environmentally friendly, and the obtained product Istradefylline is high in yield and purity, thereby having a relatively high practical value.